Biofrontera (BFRIW) Stock Analysis

What Biofrontera does

Biofrontera Inc. is a biopharmaceutical firm specializing in the commercialization of pharmaceutical solutions for skin-related ailments across the United States. Its product lineup features Ameluz, a prescription drug employed with the BF-RhodoLED lamp series for photodynamic therapy. This treatment is designed for both localized and broader area management of mild-to-moderate actinic keratosis on the face and scalp. Additionally, the company offers Xepi, a topical, non-fluorinated quinolone that functions by inhibiting bacterial growth to treat impetigo. Established in 2015, Biofrontera Inc. is headquartered in Woburn, Massachusetts.

Key metrics

ETFs linked to BFRIW

Broad-market and Healthcare sector ETFs an investor holding Biofrontera is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how BFRIW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Biofrontera?

Biofrontera trades under the ticker BFRIW on NASDAQ.

Which exchange is BFRIW listed on?

BFRIW is listed on NASDAQ.

What sector does Biofrontera operate in?

Biofrontera is classified in the Healthcare sector (Medical - Pharmaceuticals industry).

How can PortView help analyze BFRIW in a portfolio?

PortView shows BFRIW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.